NASDAQ: TVTX

Travere Therapeutics (TVTX) Stock Analysis & Forecast

Nov 13 close

$50.65−0.91 (−1.8%)

Gekko Brief

Nov 9 close

Travere Therapeutics closed at $51.63 on 9 November 2026, +4.1% on the day. The price sits between the 50-day ($57.12) and 200-day ($47.26) moving averages, inside a 52-week range of $22.59 to $68.73. The GekkoIndex reads 62.3, in the Accumulation zone, down 6.8 points over five sessions. Gekko Fair Value is $64.48, so the price is 19.9% below it.

The next earnings report is due on 18 February 2027, 95 days away (after close). Over the last 8 reports the company beat the earnings estimate 4 times, with an average move of 6.6% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +4.3% over the last 5 years, rising in 3 of them.

11 firms rate the stock: 10 buy, 1 hold and 0 sell, with a consensus target of $75.14. A typical daily move is about 5.3%, and a typical 20-day move about 11.1%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.

A plain summary of the figures as of the Nov 9, 2026 close.

Travere Therapeutics price vs fair value

$62.93$50.65Nov ’25May ’26Nov ’26
Close $50.65200-day averageGekko Fair Value $62.93

Travere Therapeutics quick facts

Market cap
$4.86B
P/E ratio
—
Forward P/E
25.8
EPS, TTM
−$1.67
Revenue, TTM
$651.0M
Profit margin
-18.7%
Dividend yield
—
Beta
1.12
Volume
696,210 avg 2.20M
1-year return
+38.9%
Typical daily move
±5.2%
Typical 20-day move
±11.1%
50-day average
$55.93
200-day average
$47.68
Next earnings
Feb 18 after close
Shares outstanding
95.99M
52-week range
$22.59$68.73

Travere Therapeutics swing-trade checklist

Travere Therapeutics scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $50.65 sits between the 50-day ($55.93) and 200-day ($47.68) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    60.5, Accumulation

    Reading 60.5 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    19.5% below

    Price is 19.5% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +4.1% on average

    From this point in the calendar, the next 20 trading days averaged +4.1% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Travere Therapeutics stock chart and price history

Travere Therapeutics closed at $50.65 on Nov 13, 2026, +38.9% over the past year, inside a 52-week range of $22.59 to $68.73.

Close50-day average200-day averageVolume
Travere Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$20$30$40$60$70DecJan 2026FebMarAprMayJunJulAugSepOctNov50.65

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−4.1%
3 months
−20.3%
6 months
+18.9%
1 year
+38.9%
The full TVTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TVTX in Gekko

Follow Travere Therapeutics through every session

Put TVTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track TVTX in GekkoFree for 7 days. No credit card required.

About Travere Therapeutics

Travere Therapeutics focuses on treatments for rare conditions affecting the kidneys and metabolism. Its best-known product is FILSPARI, an oral, once-daily medicine that works against two biological pathways linked to disease progression and has been approved to slow kidney decline in adults with primary IgA nephropathy at risk of worsening, and later cleared to reduce proteinuria in patients eight and older with focal segmental glomerulosclerosis without nephrotic syndrome, a condition for which it stands as the only approved medicine of its kind.

Beyond FILSPARI, the company sells Thiola and Thiola EC, tiopronin tablets used to treat cystinuria, a genetic disorder that causes repeated kidney stones. It is also developing pegtibatinase, an experimental enzyme replacement therapy aimed at classical homocystinuria, which remains in its pipeline rather than on the market. Its customers are patients and physicians treating these rare inherited and progressive diseases.

The company was previously known as Retrophin, Inc. before adopting the Travere name in November 2020. It is based in San Diego, California, and incorporated in Delaware. Travere Therapeutics is listed on the NASDAQ under the ticker TVTX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
travere.com

Travere Therapeutics GekkoIndex: the smart money zone

Travere Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.5, in the Accumulation zone, down 5.8 points over five sessions.

010060.5Accumulation

Down 5.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying32−0.7%+5.7%+14.3%+23.9%
Accumulation (current zone)188+0.9%+1.7%+4.6%+21.9%
Neutral426+1.9%+3.8%+7.4%+19.1%
Distribution52+3.4%+4.0%+8.1%+28.8%
Selling4Too few readings yet

Average TVTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the TVTX price, zone by zone.Track TVTX in Gekko

Is Travere Therapeutics stock overvalued? Gekko Fair Value

Travere Therapeutics trades 19.5% below Gekko Fair Value of $62.93, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Travere Therapeutics shares are worth, recalculated every trading day.

$62.93

Gekko Fair Value, Nov 14, 2026

19.5% Undervalued

At the end of Aug 2026 the price was 4.0% below the estimate.

Gekko Fair ValueShare price, month end
$63$51Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open TVTX in Gekko

Travere Therapeutics insider and Congress trading

No open-market insider purchases were filed for Travere Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for TVTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every TVTX insider filing, plotted on the chart in Gekko.Open TVTX in Gekko

Congress trades last 90 days

No trades in TVTX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for TVTX, plotted on the chart in Gekko.Open TVTX in Gekko

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 6, $488K in unusual premium.

Hedge funds and billionaires quarter ended Sep 30

1of the funds Gekko tracks holds TVTX.

1added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Travere Therapeutics earnings: next date and track record

Travere Therapeutics reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±6.6%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

−5.8%Feb ’25+1.6%May ’25+1.4%Aug ’25+17.3%Oct ’25+9.0%Feb ’26+1.5%May ’26+14.2%Aug ’26−1.9%Nov ’26

Last earnings call, Nov 2, 2026 AI summary

What they said
Travere Therapeutics reported Q3 2026 quarterly net product sales surpassing $200 million for the first time, driven by FILSPARI in IgA nephropathy and FSGS. Strong patient demand, growing conversion rates, and high adherence supported revenue growth despite new market entrants. The company is undergoing a CEO transition with Bradley taking over December 1. Patent portfolio was strengthened with new IgAN patent extending to 2037 and FSGS notice of allowance.
Guidance
Management reaffirmed confidence in achieving or exceeding $3 billion in annual FILSPARI sales by 2033, citing durable recurring revenue from growing patient base and expanding FSGS opportunity. CEO transition expected December 1 with continued commercial momentum.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026−$0.55
est −$0.10
−458.8%$224.6M
est $195.3M
+15.0%−1.9%
Aug 4, 2026−$0.37
est −$0.14
−164.3%$169.6M
est $157.3M
+7.8%+14.2%
May 4, 2026$0.05
est −$0.06
+183.3%$127.2M
est $136.2M
−6.6%+1.5%
Feb 19, 2026$0.03
est $0.03
0.0%$129.7M
est $144.6M
−10.3%+9.0%
Oct 30, 2025$0.28
est −$0.31
+190.3%$164.9M
est $147.0M
+12.2%+17.3%
Aug 6, 2025$0.13
est $0.04
+225.0%$114.4M
est $99.55M
+15.0%+1.4%
May 1, 2025−$0.19
est −$0.39
+51.3%$81.73M
est $88.80M
−8.0%+1.6%
Feb 20, 2025−$0.47
est −$0.38
−24.1%$74.79M
est $72.38M
+3.3%−5.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Travere Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Travere Therapeutics is $73.43, +45.0% from the last close, from 11 firms rating the stock in the last 90 days.

$73.43consensus 12-month target, +45.0% from the last close
Low $62High $80
Buy10
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5Leerink PartnersBuy, maintained$67+32.3%
Nov 4Canaccord GenuityBuy, maintained$72+42.2%
Nov 3Cantor FitzgeraldBuy, maintained——
Nov 3H.C. WainwrightBuy, reiterated$67+32.3%
Nov 3Wells FargoBuy, reiterated$80+57.9%
+4.6%average 20-day move after past Accumulation readings
+4.1%average move over the next 20 trading days in the last 5 years
±5.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Travere Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Travere Therapeutics averaged +4.1% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−10.3%2021−12.8%2022+46.1%2023−6.2%2024+0.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−3.7%2 of 5
Next 10 trading days−1.5%3 of 5
Next 15 trading days+4.6%2 of 5
Next 20 trading days+4.1%2 of 5
Next 30 trading days+11.1%3 of 5

For scale, TVTX’s typical 20-trading-day move in either direction is about 11.1%.

Travere Therapeutics market cap and key statistics

Travere Therapeutics’s market cap is $4.86B and revenue of $651.0M over the last twelve months.

Valuation

Market cap
$4.86B
Forward P/E
25.8
EPS, TTM
−$1.67
Gekko Fair Value
$62.93

Trading

Volume
696,210
Avg volume, 20 days
2.20M
52-week high
$68.73
52-week low
$22.59
Shares outstanding
95.99M

Financials

Revenue, TTM
$651.0M
Profit margin
-18.7%
Return on equity
-321.2%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.12
Typical daily move
±5.2%
Typical 20-day move
±11.1%

Travere Therapeutics peers

Travere Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Travere Therapeutics stock FAQ

What is Travere Therapeutics’s market cap?

Travere Therapeutics’s market cap is $4.86B at the Nov 13, 2026 close of $50.65, with 95.99M shares outstanding.

What is the Travere Therapeutics stock forecast?

The consensus analyst 12-month price target for Travere Therapeutics is $73.43, +45.0% from the last close. Of the 11 firms that rated the stock in the last 90 days, 10 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Travere Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Travere Therapeutics is undervalued: the Nov 13, 2026 close of $50.65 is 19.5% below Gekko Fair Value of $62.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Travere Therapeutics report earnings next?

Travere Therapeutics is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of $0.44 per share on revenue of $247.5M. Travere Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 6.6% on average across the report.

What is Travere Therapeutics’s 52-week high and low?

Travere Therapeutics’s 52-week high is $68.73 and its 52-week low is $22.59; it closed at $50.65 on Nov 13, 2026, +38.9% over the past year.

Is Travere Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Travere Therapeutics?

Gekko flagged 1 unusual options signal in Travere Therapeutics over the last 30 days, with $488K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 6, 2026 with $488K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Travere Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.